ID   BC-3
AC   CVCL_1080
SY   BC3
DR   BTO; BTO:0002722
DR   CLO; CLO_0001891
DR   EFO; EFO_0002046
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2277
DR   BioGRID_ORCS_Cell_line; 1098
DR   BioSample; SAMN03472835
DR   BioSamples; SAMEA365848
DR   BioSamples; SAMEA365859
DR   cancercelllines; CVCL_1080
DR   CCRID; 3101HUMSCSP5016
DR   CCTCC; GDC0221
DR   Cell_Model_Passport; SIDM00895
DR   ChEMBL-Cells; CHEMBL3308890
DR   ChEMBL-Targets; CHEMBL2366371
DR   Cosmic; 687836
DR   Cosmic; 910918
DR   Cosmic; 1238077
DR   Cosmic; 1515188
DR   Cosmic; 1588558
DR   Cosmic-CLP; 910918
DR   DepMap; ACH-002215
DR   DSMZ; ACC-679
DR   DSMZCellDive; ACC-679
DR   GDSC; 910918
DR   GEO; GSM33135
DR   GEO; GSM38796
DR   GEO; GSM38797
DR   GEO; GSM634733
DR   GEO; GSM710419
DR   GEO; GSM710435
DR   GEO; GSM1669611
DR   GEO; GSM3150237
DR   IARC_TP53; 21190
DR   IARC_TP53; 26979
DR   IGRhCellID; BC3
DR   LINCS_LDP; LCL-1948
DR   PharmacoDB; BC3_79_2019
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1080
DR   PubChem_Cell_line; CVCL_1080
DR   Wikidata; Q54795189
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   Patent=US5908773;
RX   PubMed=8839859;
RX   PubMed=9766492;
RX   PubMed=15613351;
RX   PubMed=17121789;
RX   PubMed=19608668;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21685375;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   https://cornell.flintbox.com/technologies/d21d6b39-b480-4ad4-8785-cc7a70c91788
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-2277.
CC   Population: Caucasian.
CC   Doubling time: ~50-60 hours (DSMZ=ACC-679).
CC   HLA typing: A*02:05:01,03:01:01; B*14:02:01,50:01:01; C*06:02:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01; DQA1*02:01:01,01:01:02; DQB1*02:02:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*01:02:01,07:01:01 (DSMZCellDive=ACC-679).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19608668).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=7.13%; Native American=1.02%; East Asian, North=6.58%; East Asian, South=0%; South Asian=6.31%; European, North=25.3%; European, South=53.67% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 14,21.2
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 24,25
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 14,16
ST   FGA: 18,22
ST   Penta D: 8,13
ST   Penta E: 7,15
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_4J72 ! KS-1 [Human primary effusion lymphoma]
SX   Male
AG   85Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   Patent=US5908773;
RA   Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.;
RT   "KSHV positive cell lines.";
RL   Patent number US5908773, 01-Jun-1999.
//
RX   PubMed=8839859; DOI=10.1182/blood.V88.7.2648.bloodjournal8872648;
RA   Arvanitakis L., Mesri E.A., Nador R.G., Said J.W., Asch A.S.,
RA   Knowles D.M., Cesarman E.;
RT   "Establishment and characterization of a primary effusion (body
RT   cavity-based) lymphoma cell line (BC-3) harboring Kaposi's
RT   sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of
RT   Epstein-Barr virus.";
RL   Blood 88:2648-2654(1996).
//
RX   PubMed=9766492; DOI=10.1038/sj.leu.2401160;
RA   Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.;
RT   "Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
RT   effusion lymphomas (body cavity-based lymphomas).";
RL   Leukemia 12:1507-1517(1998).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=17121789; DOI=10.1128/JVI.01757-06;
RA   Burd C.E., Sin S.-H., Dittmer D.P.;
RT   "Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus
RT   lymphomas: implications for therapy.";
RL   J. Virol. 81:1912-1922(2007).
//
RX   PubMed=19608668; DOI=10.3324/haematol.2009.007260;
RA   Boulanger E., Marchio A., Hong S.-S., Pineau P.;
RT   "Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin
RT   genes in human herpesvirus 8-associated primary effusion lymphoma.";
RL   Haematologica 94:1170-1174(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//